A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects With Chronic Hepatitis B Virus Infection

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imdusiran (Primary) ; Tenofovir alafenamide (Primary) ; Vebicorvir (Primary) ; Entecavir; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Adverse reactions; Proof of concept
Sponsors Assembly Biosciences

14 Nov 2023 Results of additional end of treatment data and preliminary off-treatment responses presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
11 Oct 2023 According to an Assembly Biosciences media release, data from this study will be presented at the upcoming American Association for the Study of Liver Diseases (AASLD)
31 Mar 2023 Status changed from active, no longer recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com